Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × Erlotinib Hydrochloride × Clear all

Phase

Status

Completed 131 Terminated 30 Active not recruiting 6 Withdrawn 3 Unknown 3 Suspended 1 Recruiting 1

Sponsor Class

OTHER 5 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 220 Carboplatin 159 Injections 116 Paclitaxel 110 Cisplatin 110 Bevacizumab 102 Gemcitabine 101 Pemetrexed 77 Docetaxel 74 Cyclophosphamide 54 Capecitabine 52 Fluorouracil 50 Oxaliplatin 47 Nivolumab 45 Fulvestrant 45 Cetuximab 45 130-nm albumin-bound paclitaxel 43 Dexamethasone 40 atezolizumab 39 Rituximab 38 Leucovorin 37 fludarabine 36 venetoclax 34 toripalimab 33 Lenalidomide 32 Drug Therapy 32 enzalutamide 31 durvalumab 30 trastuzumab deruxtecan 28 Prednisone 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05442060 2025-08-03

EGFR

OBI Pharma, Inc

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡